Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Evidence-Based Evaluation of Cost-Effectiveness and Clinical Outcomes Group, Pharmaceutical Sciences Research Center (PSRC), and the Pharmaceutical Management and Economics Research Center (PMERC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Daru. 2020 Dec;28(2):799-805. doi: 10.1007/s40199-020-00358-5. Epub 2020 Jul 3.
The novel coronavirus disease 2019 (COVID-19) was characterized as a global pandemic by the WHO on March 11th, 2020. This pandemic had major effects on the health market, the pharmaceutical sector, and was associated with considerable impacts; which may appear in short and long-term time-horizon and need identification and appropriate planning to reduce their socio-economic burden.
Current short communication study assessed pharmaceutical market crisis during the COVID-19 era; discussing short- and long-term impacts of the pandemic on the pharmaceutical sector.
Short-term impacts of COVID-19 pandemic includes demand changes, regulation revisions, research and development process changes and the shift towards tele-communication and tele-medicine. In addition, industry growth slow-down, approval delays, moving towards self-sufficiency in pharm-production supply chain and trend changes in consumption of health-market products along with ethical dilemma could be anticipated as long-term impacts of COVID-19 pandemic on pharmaceutical sector in both global and local levels.
The pandemic of COVID-19 poses considerable crisis on the health markets, including the pharmaceutical sector; and identification of these effects, may guide policy-makers towards more evidence-informed planning to overcome accompanying challenges. Graphical abstract .
2020 年 3 月 11 日，世界卫生组织（WHO）将 2019 年新型冠状病毒病（COVID-19）定性为全球大流行。这场大流行对医疗市场和制药行业产生了重大影响，并带来了相当大的冲击；这些影响可能在短期和长期显现，需要加以识别并进行适当规划，以减轻其对社会经济的负担。
本短讯研究评估了 COVID-19 时代的制药市场危机，讨论了大流行对制药行业的短期和长期影响。
COVID-19 大流行的短期影响包括需求变化、法规修订、研发过程变化以及向远程通信和远程医疗的转变。此外，预计 COVID-19 大流行对制药行业在全球和地方层面的长期影响还包括行业增长放缓、审批延迟、向药品生产供应链自给自足转变以及医疗市场产品消费趋势变化以及出现伦理困境。
COVID-19 大流行对医疗市场造成了重大危机，包括制药行业；识别这些影响，可以指导决策者制定更多基于证据的规划，以克服伴随而来的挑战。
